Enseval Putera Megatrading Tbk PTEPMT:JKT

3,000
0.00 / 0.00%
0
15.49%
0.5378
Close in IDRToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 24 2014 10:00 BST.

About the company

16.56tn465.47bn19895.19k
Revenue in IDR (TTM)Net income in IDRIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
Enseval Putera Megatrading Tbk PT
Jl. Pulo Lentut No. 10
Kawasan Industri Pulogadung
JAKARTA TIMUR13920
Indonesia
IDN
Phone+62 214600200Fax+62 214609049Websitehttp://www.enseval.com
PT Enseval Putera Megatrading Tbk is an Indonesia-based company primarily engaged in distributing and trading pharmaceutical and consumer products. Its business is classified into four divisions: pharmaceutical products, comprising various ethical drugs; consumer products, comprising over-the-counter (OTC) drugs, nutritional supplements and other consumer goods; medical devices, and chemical materials, including the raw materials used in manufacturing veterinary medicines, pharmaceutical drugs, cosmetics and food. The Company operates a warehouse in Jakarta, Indonesia to distribute its products to the west regions of Indonesia. It also operates a warehouse in Surabaya, Indonesia as a distribution centre for the east regions of Indonesia. Both warehouses are equipped with refrigerated storages. The Company has numbers of branch offices throughout Indonesia to support its distribution activities.

Mergers & acquisitions

There are no recent mergers or acquisitions for Enseval Putera Megatrading Tbk PT.
Data delayed at least 15 minutes, as of Oct 24 2014 10:00 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
Unisplendour Guhan Group Corporation Ltd
345.80bn-354.59bn7.07tn1.86k--13.17--20.44-0.8039-0.80390.78391.220.29641.753.4894,074.82-30.39620.2554-47.34280.255448.2252.68-102.54290.27610.8711--0.00371,409.54-29.5581.59-219.508--1.44--
Dalian Merro Pharmaceutical Co.,Ltd
686.16bn98.18bn7.13tn54772.603.77--10.390.1420.1420.99262.730.23484.074.22635,0893.372.313.712.3120.4514.5214.373.081.80--0.040122.42-43.7343-19.497213.855.9023.0535.22
Shanghai Furen Industrial (Group) Co.
794.54bn43.11bn7.30tn1.24k169.4112.67--9.190.12290.12292.271.640.41381.684.20324,6682.708.785.328.7838.5138.706.537.610.80062.170.60710.0012.415.5476.70-10.409727.28--
Shandong Wohua Pharmaceutical Co., Ltd.
583.76bn38.67bn7.63tn1.06k197.246.33--13.070.11940.11941.803.720.45653.2111.80279,0853.02-0.6123.20-0.61271.9776.596.62-2.170810.79--0.00--21.945.8527.35-27.1716-22.9794--
Ginwa Enterprise (Group) Inc.
1.24tn86.63bn7.69tn76588.813.83--6.190.14370.14372.063.330.52615.795.41822,7563.586.514.226.5153.5744.086.8013.891.73--0.0016.682.37-2.03933.03---12.7789--
Chengdu Huasun Group Inc Ltd
1.27tn87.82bn8.07tn99691.927.05--6.370.11550.11551.671.510.66326.161.85644,6254.594.927.694.9239.1133.536.934.521.2617.080.263335.4513.3112.6148.6857.84-6.8115--
Guangdong Taicheng Pharmaceutical Co Ltd
----8.25tn510------------------------------------------------0.5556--2.52------
Shanxi C&Y Pharmaceutical Group Co Ltd
1.28tn75.47bn8.46tn1.68k112.066.82--6.620.28560.28564.834.690.67063.808.50384,0065.329.346.999.3467.3353.537.9310.311.7911.220.097122.6942.0520.325.0815.77130.90--
Medigen Biotechnology Corporation
83.52bn-186.03bn7.12tn67--5.67--85.30-3.4577-3.45771.5522.820.06612.766.76---16.6766-9.6941-20.4534-9.694129.1267.62-252.197-126.79263.51--0.1081---34.3386-11.7712-244.3001--24.66--
Lotus Pharmaceutical Co Ltd
253.76bn-72.79bn7.73tn297--4.75--30.46-2.4584-2.45848.9817.720.42441.666.56---12.1724-5.029-14.7363-5.02955.9059.66-28.685-6.95645.90--0.2152--30.873.59106.16-21.64624.72--
Strides Arcolab Limited
1.89tn1.40tn7.86tn2.70k5.541.955.374.15121.15143.91158.65344.580.18931.071.88--14.04--26.16--48.86--74.18--0.53890.87770.3882--------------
Bukwang Pharmaceutical Co., Ltd.
1.54tn258.76bn7.19tn58225.723.0521.254.67799.10799.104,800.196,744.9------252,503,100--------55.81--16.81--7.10--0.00---11.3406--18.29------
Dong-A Socio Holdings Co Ltd
6.80tn133.93bn7.23tn33882.641.3418.291.061,790.971,790.97137,248110,2810.62113.498.101,832,384,0001.606.482.826.4832.1047.512.587.420.60884.710.427517.9217.75-5.6514-83.2377-34.57138.22-12.7768
LG Life Sciences, Ltd
4.51tn-49.85bn7.31tn1.40k--2.6325.571.62-267.317-267.31724,191.0914,774.140.66071.954.51284,609,800-0.69313.22-0.93933.2248.4347.27-1.04913.300.82670.80450.53320.002.798.16-61.7732-26.462212.82--
Enseval Putera Megatrading Tbk PT
16.56tn465.47bn8.13tn5.19k17.462.4914.230.4907171.85171.856,114.151,203.192.936.848.443,757,039,0008.2316.7015.1216.7011.4011.362.813.121.0232.320.0508--16.8316.1415.2911.7126.13--
Data as of Nov 01 2014. Currency figures normalised to Enseval Putera Megatrading Tbk PT's reporting currency: Indonesian Rupiah IDR.
Data delayed at least 20 minutes, as of Oct 31 2014 20:58 GMT.

Institutional shareholders

HolderShares% Held
RHB Asset Management Sdn Bhd.
as of 31 Mar 2014
00.00%
Forward Management LLC
as of 31 Aug 2014
00.00%
0.00%
Per cent of shares
held by top holders
Data from 30 Jun 2014 - 30 Jun 2014Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.